Trial Profile
A Randomized Study of Two Doses Gemtuzumab Ozogamicin vs. A Two-year Maintenance With Atra Plus Chemotherapy as Post-consolidation Treatment for Intermediate and High-risk Adult Patients With Acute Promyelocytic Leukemia (Apl).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary) ; Mercaptopurine; Methotrexate; Tretinoin
- Indications Acute promyelocytic leukaemia
- Focus Therapeutic Use
- Sponsors Wyeth
- 31 Aug 2009 New trial record